/Investor DB

Point72 — 2024 Investments

2 investments dated 2024 · listed companies and verified rows first · show all

Hinge Biohingebio.cominDec 2024✓ verified

Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.

BiotechHealthtechBurlingame, US

Daniel J. Capon(Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)inHarold E. "Barry" Selick(Chief Executive Officer & Director)Paul Brunetta(Chief Medical Officer)in

Co-investorsAgent CapitalBaruch Future VenturesInVivium CapitalRidgeback Capital

Incogniaincognia.comin𝕏Jan 2024 · $31M

Incognia provides device intelligence and identity verification solutions combining device recognition, location analysis, and tamper detection for fraud prevention and user verification.

AI & Machine LearningCybersecurityData & InfrastructureFintechSan Jose, US

Andre de Souza Ferraz(Chief Executive Officer)André F.(Founder)inAlan Gomes(Founder)inAdam Kagan Carson(Director)Patricia de Moraes(Director)Arthi Rajan Makhija(Director)

Co-investorsBessemer Venture PartnersFJ LabsPoint72 VenturesPortag3 VenturesPortage VenturesValor Capital Group+1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.